Biometrics: Award

Showing posts with label Award. Show all posts

IBM Receives Frost & Sullivan Customer Value Leadership Award for its Mobile Identity and Access Management Solutions

MOUNTAIN VIEW, Calif., May 20, 2014 /PRNewswire/ -- Based on its recent analysis of mobile authentication, Frost & Sullivan recognizes IBM with the 2014 Global Frost & Sullivan Award for Customer Value Leadership. Central to the company's success in generating value for customers is the integration of various mobile security, mobile identity, and access management solutions. IBM's strong value proposition with regards to the provisioning of context-based authentication for multiple mobile device types and mobile applications has also been instrumental to its success.

"When it comes to identity and access management, organizations often face a trade-off between improving security levels and delivering greater end-user convenience," said Frost & Sullivan Senior Industry Analyst Mario Fernandez. "IBM breaks the security/end-user convenience trade-off through its IBM Security Access Manager for Mobile appliance."

The IBM Security Access Manager for Mobile appliance's risk engine determines the risk of an end user's authentication attempt by comparing it with a historical behavior profile of that user, which contains information related to the volume, type and frequency of transactions; Internet protocol reputation; geographic location; and device fingerprinting. On ascertaining the risk, the appropriate authentication method is applied. While low-risk access attempts require simple authentication methods such as a password, high-risk access attempts might involve hardware or software one-time password tokens.

To determine the appropriate authentication method, the IBM Security Access Manager for Mobile risk engine also pays heed to the application or data that the end user wants to access. For instance, if an end user wants to access a business-critical application or confidential data, then they must use an authentication method with a high degree of irrefutability. Essentially then, security becomes context-based and organizations can establish—and seamlessly enforce—access management policies without introducing greater end-user inconvenience.

The value proposition of IBM's Security Access Manager for Mobile appliance is enhanced through the integration of other IBM products, including IBM Security Access Manager for Web, which adds content security capabilities to protect against attacks such as SQL injection and cross-site scripting. Likewise, IBM's Federated Identity Manager, which supports the Security Assertion Markup Language (SAML), WS-Federation and OpenID standard protocols, can enable federated single sign-on. This facilitates the integration of cloud services, such as Google Apps or Office 365, which also support the above-mentioned protocols.

In a bid to remain ahead of its competitors, IBM added two important security companies and their corresponding products to its portfolio in 2013—Trusteer and Fiberlink. The company has also drawn up a future-proof product roadmap that recognizes that biometric authentication methods and contactless technologies will play a prominent role in enabling mobile access.

"Already, IBM's scientists have developed an algorithm to determine biometric-based authentication risk scores and risk analysis that can be incorporated into IBM Security Access Manager for Mobile," said Fernandez.

Each year, Frost & Sullivan presents this award to the company that demonstrates excellence in implementing strategies that proactively create value for its customers with a focus on improving the return on the investment that customers make in its services or products. This award recognizes the company's inordinate focus on enhancing the value that its customers receive, beyond simply good customer service, leading to improved customer retention and, ultimately, customer base expansion.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About IBM Security

IBM Security offers one of the most advanced and integrated portfolios of enterprise security products and services. The portfolio, supported by world-renowned IBM X-Force research and development, provides the security intelligence to help organizations protect their people, data, applications and infrastructure. IBM offers security solutions for identity and access management, database security, application development, risk management, endpoint management, next-generation intrusion protection and more. IBM operates one of the world's broadest security research and development, and delivery organizations. IBM monitors 15 billion security events per day in more than 130 countries and holds more than 3,000 security patents. For more information on IBM security solutions, X-Force reports, and webinars, please visit: www.ibm.com/security.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies? Contact us: Start the discussion.

Contact:

Mireya Espinoza
P: 210. 247.3870
F: 210.348.1003
E: mireya.espinoza@frost.com

Jacqueline McCouat
P: + 44 7768 504084
E: jacqueline.mccouat@uk.ibm.com

SOURCE Frost & Sullivan

DERMALOG Wins IAIR Global Award for Innovation and Technological Leadership

HONG KONG, March 3, 2014 /PRNewswire/ --

Biometrics at its best: for the development of pioneering technological solutions in biometric identification, DERMALOG has been awarded with the world-renowned IAIR Global Award in the category "Innovation and Leadership". With its innovative fingerprint-based identification systems, DERMALOG is the market leader in biometrics for government, commercial and bank applications.

Hamburg biometrics expert DERMALOG Identification Systems GmbH was awarded with the IAIR Global Award 2014 in the business metropolis of Hong Kong on Friday evening in the category "Innovation and Leadership - regional" pays tribute to the leading role that the Hamburg-based company is playing in the area of biometrics, fingerprint scanners and AFIS (automatic fingerprint identification systems).

The biometric innovations from DERMALOG are unique in the world. The company sets new standards in the matching speed of fingerprints: its "Next Generation AFIS" is capable of correctly identifying the ten fingerprints of an individual with a matching speed of 129 million matches per second. In addition to this, the world's most secure liveness detection feature prevents fraud during the identification scan, because it recognizes plastic fingers and other fakes automatically. DERMALOG's technologies in the area of sensor development and production have already received three awards as market leaders.

Furthermore the company excels with its innovative solutions for the practical application of biometric identification. The LF10 fingerprint scanner is a pioneer for rolled fingerprints and tenprints. A groundbreaking additional function enables it to record and capture signatures on the same scanning window as fingerprints. This means that, other than a pen, no signature pad is required.

Hamburg biometrics company is the market leader in many parts of the world

The IAIR Award for "Innovation and Leadership" is awarded to outstanding companies whose products optimizes processes and implement sustainable progress. The specialist jury considers the company DERMALOG with its unique expertise in the area of fingerprint biometrics to be a leader in many regions throughout the world, especially in Asia where DERMALOG has successfully implemented extensive major national systems.

Thanks to ongoing developments and innovations, the award-winning technologies are now being used in more than 110 large government installations in more than 60 countries, ensuring greater security and fraud free. The company is the world's fastest-growing biometrics firm. Even now, the Hamburg manufacturer is the world's market leader in many areas of application, such as biometric identification at banks, commercial and at many government institutions.

"We are delighted to accept this internationally recognized award," says Günther Mull, managing director of DERMALOG. "This award shows once more that our technologies are experiencing an increase in security recognition and acceptance in the world market. The knowledge we are gaining through our growing international activity provides invaluable feedbacks into the further research and development of our products. It is our goal to provide biometric identification systems that are ever simpler and faster."

The company is able to offer biometric components and complete solutions. It often works together with local system integrators. "This means we can develop tailor-made solutions based on our technologies, both for companies and governments," Mull explains.

In addition to bank, commercial and government applications such as national border control systems, biometric identification cards and passports, DERMALOG's technology is also used for biometric computer login. The focus here is on providing the greatest security for sensitive user data, but also simple handling. "With fingerprint identification, the problem of having to remember various PIN numbers already belongs to the past in some parts of the world, and in the long term it will completely disappear from people's daily lives," says Günther Mull.

DERMALOG Identification Systems GmbH, based in Hamburg, is Germany's largest biometrics manufacturer and is a world leader in biometric identification. A team of scientists and computer scientists work continuosly on new,innovative products. The company's product portfolio ranges from biometric border control and biometric ID cards to new "FingerLogin" and "FingerPayment" solutions. In addition to Germany and Europe, DERMALOG's main markets are primarily Asia, Latin America, Africa and the Middle East.

In Germany, DERMALOG has supplied more than 20,000 fingerprint scanners for local national registration offices and immigration authorities. This means that fingerprints are recorded in new passports, ID cards and residency permits. The company has also supplied another 80,000 finger scanners in more than 60 countries. Large AFIS installations (automatic fingerprint identification systems) made by DERMALOG can now be found at more than 110 government clients throughout the world. DERMALOG also provides systems for banks and ATM manufacturers such as Wincor, which has already equipped more than 1,000 ATMs worldwide with DERMALOG's fingerprint technology, allowing fingerprints to replace insecure PIN numbers.

More information is available at:

http://www.dermalog.com.

Press contact
For further information, please contact:
DERMALOG Identification Systems GmbH
Oliver von Treuenfels
Mittelweg 120
20148 Hamburg
Telephone: +49(0)40-413227-0
Fax: +49(0)40-413227-89
Email: Oliver.vonTreuenfels@dermalog.com

SOURCE DERMALOG Identification Systems GmbH

reade more...

Adrian Bird wins the Frontiers of Knowledge Award for mapping gene activation and introducing new prospects to cure neurological disorders

MADRID, Jan. 28, 2014 /PRNewswire/ -- The sixth annual BBVA Foundation Frontiers of Knowledge Award in the Biomedicine category goes to British biochemist Adrian Bird, "for his discoveries in the field of epigenetics." Bird's achievements includes mapping DNA regions where genes are activated by the addition of a type of molecule known as a methyl group, in a process known as methylation. This contribution is of a fundamental nature, since DNA methylation, as the jury explains, "plays a crucial role in many diseases and in the progression of nearly all types of cancer."

In the words of the award citation: "In a mammal, all cells have the same DNA sequence. However, cells involved in different functions express distinct subsets of genes. These different expression patterns are stabilized through epigenetic marks, of which DNA methylation was the first to be discovered and characterized. DNA methylation marks are inherited as cells divide, and in some cases inherited across generations."

His work on methylation would later lead Bird to a discovery which could prove game-changing in the neurosciences domain. In experiments with mice, he found that by correcting defects in a protein associated with a severe form of autism known as Rett syndrome, the symptoms of the condition disappeared. "This is the first time that a neurological disease has been reversed in an experimental context, and offers hope that this approach can be translated into the clinic," the citation continues.

This result, obtained in 2007, has refocused research efforts on this congenital condition, which affects girls – one in every 10,000 – and causes severe mental retardation and the progressive and persistent loss of cognitive and motor skills. Bird has since combined his basic research with an active involvement in the quest "to do in humans what we have done in mice," he explained on the phone yesterday. "I used to be quite content with myself just pursuing knowledge. But to see that your research can have such practical relevance in people's lives adds a new dimension, and makes the whole thing more exciting and engaging," he remarked during the same conversation, after stating his surprise and gratitude for the jury's decision.

Importance in cancer and aging

Epigenetic changes in the genome occur naturally during embryonic development and throughout life. They are also the mechanism through which the environment impacts our genes – smoking, for instance, affects DNA methylation. So understanding how these changes happen is a vital first step in order to understand diseases like Rett syndrome, and clarify the ways in which lifestyle and environmental factors influence cancer.

"DNA methylation is organized in a pattern, which is slightly different in each cell. And in the case of cancer cells, we know that these patterns are really messed up," Bird explains. "Although the relationship between DNA methylation and cancer is not fully understood, it seems pretty clear that certain genes in the tumor cell that depend on the absence of methylation become methylated and are shut down in consequence, which facilitates the development of cancer."

By the late seventies, scientists knew a relationship existed between methylation and gene activation, but not how it worked. Bird obtained the first ever DNA methylation map, defining the regions where the process unfolds.

New hope for Rett syndrome

Bird not only revealed the precise form of organization of "the regions within the genome marked by DNA methylation," the jury remarks, but also "identified proteins that read the DNA methylation signals, mutation of which leads to human diseases."

His discovery of the MeCP2 protein that detects methylation signals in the genome occurred in the early nineties, before the human genome was sequenced. It was therefore a "huge surprise" to me and everyone, recalls Bird; once he was able to show, at the end of that decade, that it was a mutation in this protein that causes Rett syndrome.

Even more remarkable was his achievement in reversing the disorder in an animal model. In 2001, Bird switched research tactics and created a mouse with the Rett syndrome genetic defect, presenting all the symptoms of the disease. In 2007, he found a way to activate the correct protein in these laboratory animals, and the symptoms disappeared.

"We didn't expect it because it was assumed that once you have a neurological disorder, you have it forever. We thought we might, with luck, delay the animals' death or perhaps alleviate some of the symptoms," Bird reflects. "But what we got was a clear result, a spectacular improvement. It was one of those Eureka moments."

The new laureate explained at a press event this morning that his experiment to treat mice with Rett syndrome started from the fact that the disease is not accompanied by the death of neurons, so it was theoretically possible to restore them to a fully functional state. This characteristic is shared by fragile X syndrome, another disabling hereditary disorder.

"We are still far from finding a cure for these diseases, but our work provides a proof of concept that has got a lot of other research groups involved in the search for therapies."

Bird admits to feeling pressured by the thought of people waiting for a cure and "frustrated" at the failure, so far, to replicate his results in human subjects. He also warns that "we cannot be sure" if the same cure will work in humans. Nevertheless, the hope felt by many families is not, in his view, unfounded: "The parents know it will take time, and that their daughters might not benefit from the advances. But they also know that there are lots of labs around the world working on curing Rett syndrome, and that wasn't the case before."

Adrian Bird was nominated for the award by David Leach, Head of the School of Biological Sciences at the University of Edinburgh

Bio notes

Sir Adrian Peter Bird earned his PhD in biochemistry from the University of Edinburgh in 1972. He then went on to occupy post-doctoral positions at the universities of Yale (United States) and Zurich (Switzerland). On returning to Edinburgh in 1975, he joined the Mammalian Genome Unit (Medical Research Council) where he would remain for eleven years. His next move was to Vienna, where he worked as a senior scientist in the Research Institute for Molecular Pathology.

In 1990, he was appointed to the Buchanan Chair of Genetics at the University of Edinburgh, a position he still holds today and which he combined for a time with the directorship of the same institution's Wellcome Trust Centre for Cell Biology.

He is a former governor of the Wellcome Trust (among the world's leading funders of medical research), serving for three years as its Deputy Chairman.

Author of more than 150 publications in international science journals, he is a Commander of the British Empire (2005) and has received numerous awards and honors, including a knighthood in 2014.

The BBVA Foundation Frontiers of Knowledge Awards

The BBVA Foundation promotes, funds and disseminates world-class scientific research and artistic creation, in the conviction that science, culture and knowledge in its broadest sense hold the key to a better future for people. The Foundation designs and implements its programs in partnership with leading scientific and cultural organizations in Spain and abroad, seeking to identify and prioritize those projects with the power to move forward the frontiers of the known world.

The BBVA Foundation established its Frontiers of Knowledge Awards in 2008 to recognize the authors of outstanding contributions and radical advances in a broad range of scientific and technological areas congruent with the knowledge map of the late 20th and 21st centuries, and others that address central challenges, such as climate change and development cooperation, deserving of greater visibility and recognition. Their eight categories include classical areas like Basic Sciences (Physics, Chemistry and Mathematics) and Biomedicine, and other, more recent areas characteristic of our time, ranging from Information and Communication Technologies, Ecology and Conservation Biology, Climate Change and Economics, Finance and Management to Development Cooperation and the innovative realm of artistic creation that is Contemporary Music.

The juries in each category are made up of leading international experts in their respective fields, whose involvement endorses the rigor of the awards and has indeed been instrumental in consolidating their prestige. The BBVA Foundation is aided in the organization of the awards by the Spanish National Research Council (CSIC), the country's premier multidisciplinary research organization. As well as proposing each jury chair, the CSIC is responsible for appointing the Technical Evaluation Committees that undertake an initial assessment of candidates and draw up a reasoned shortlist for the consideration of the juries.

In the Biomedicine category, Committee members were Dolores Gonzalez-Pacanowska, research scientist at the Instituto de Parasitologia y Biomedicina "Lopez-Neyra" (IPBLN), and coordinator of the Council's Biology and Medicine Area; Rafael Giraldo, research scientist at the Biological Research Center (CIB); V?ctor de Lorenzo, research scientist at the Spanish National Center for Biotechnology (CNB), working with an ERC Advanced Grant; Sergio Moreno, research scientist at the Instituto de Biologia Funcional y Genomica (IBFG, a joint center of CSIC and the University of Salamanca); and Angela Nieto, research scientist at the Instituto de Neurociencias de Alicante (CSIC- Miguel Hernandez University).

Biomedicine jury

The jury in this category was chaired by Angelika Schnieke, Chair of Livestock Technology in the Department of Animal Science at Technische Universitat Munchen (TUM) (Germany). The secretary was Oscar Marin, Research Professor in the Department of Developmental Neurobiology at the Instituto de Neurociencias de Alicante, a joint center of CSIC and Miguel Hernandez University (Spain). Remaining members were Dario Alessi, Director of the Protein Phosphorylation Unit, a Medical Research Council unit in the College of Life Sciences at the University of Dundee (United Kingdom); Mariano Barbacid, leader of the Experimental Oncology Group at the Spanish National Cancer Research Centre (CNIO); Robin Lovell-Badge, Head of the Division of Stem Cell Biology and Developmental Genetics at the MRC National Institute for Medical Research (United Kingdom); Ursula Ravens, Head of the Department of Pharmacology and Toxicology in the Carl Gustav Carus Medical School of Technische Universitat Dresden (TU Dresden) (Germany); and Bruce Whitelaw, Head of the Developmental Biology Division at The Roslin Institute, a basic and translational research center belonging to the University of Edinburgh (United Kingdom).

Previous laureates

The award in the last edition was shared by chemist Douglas Coleman and physician Jeffrey Friedman for "revealing the existence of the genes involved in the regulation of appetite and body weight, a discovery crucial to our understanding of human pathologies such as obesity." In the fourth edition, the award went to Alexander Varshavsky for "discovering the mechanisms involved in protein degradation." Preceding him were Shinya Yamanaka for his achievements "showing that it is possible to reprogram differentiated cells back into a state that is characteristic of pluripotent cells," and Robert Lefkowitz for "his discoveries of the seven transmembrane receptors." Finally, the winner in the inaugural edition was Joan Massague for "developing novel approaches to identify genes involved in organ-specific metastasis."

UPCOMING AWARD ANNOUNCEMENTS

Ecology and Conservation Biology

Economics, Finance and Management

www.fbbva.es

SOURCE BBVA Foundation

Hoyos Labs Receives Envisioneering Innovation & Design Award at the 2014 ShowStoppers at the Consumer Electronics Show

LAS VEGAS, Jan. 10, 2014 /PRNewswire/ -- Eureka Hall, The Venetian / Booth #75006 -- The era of usernames and passwords is finally over, and all one will need to log onto social media profiles, conduct transactions and sign into banking account are his or her biometrics and smartphone. At this year's ShowStoppers at the Consumer Electronics Show (CES), Hoyos Labs, a digital infrastructure company, received the Envisioneering Innovation & Design Award for its recently launched app, HoyosID.

This new identity assertion platform is a free, easy-to-use and virtually unhackable iPhone and Android app that uses a multi-biometric recognition system – including the face, iris and periocular region – to confirm one's identity, with a unique "liveness" component to distinguish a living person from a photograph or video.

The end-to-end technology aims to protect both consumers and corporations by leveraging smartphones as real-time biometrics pattern acquisition devices – with no need for additional hardware to carry – and moving authentication out of a browser's username and password fields and onto mobile devices at no cost to users.

"My team is honored to have been recognized by ShowStoppers at CES for the launch of HoyosID, our new identity assertion platform," said Hector Hoyos, CEO and founder of Hoyos Labs. "For years, we have collectively worked to combine our knowledge and expertise in the biometrics, IT and technology fields to create an attractive product that would secure the material of both individuals and companies in a convenient and cost-effective way, without requiring people to carry around an additional gadget to keep personal information safe."

"People are beginning to realize that we need a better system in place to keep our private material protected, and usernames, passwords and log-ins are, without a doubt, not the solution – they have failed us all too many times and are so vulnerable to hacks," Hoyos added. "Imagining a world in which all we need to access our personal accounts on the Internet is our face and a smartphone – no additional tokens – has now become a reality, and we are eager to expand the applications of this technology further into the financial services space."

Hoyos Labs is led by Hector Hoyos, whose security and defense products have helped to protect lives and properties for decades. In addition to holding multiple patents, he also invented the HBOX and EyeSwipe biometrics identity authentication technologies and founded Global Rainmakers, Inc. (later renamed EyeLock Corp.).

For more information on Hoyos Labs and HoyosID, please visit: www.hoyoslabs.com. The app will be available for download later this quarter.

About Hoyos Labs
Hoyos Labs is a digital infrastructure security company with security, computer vision and biometrics and big data experts. The goal of Hoyos Labs is to develop and deploy enterprise and consumer identity assertion technology platforms that will conveniently and securely address the identity assertion challenges of today. Hoyos Labs currently has offices in New York, Boston, Bucharest (Romania) and Beijing (China).

Media Contacts:
Samantha Wolf / Caitlin Kasunich
KCSA Strategic Communications
swolf@kcsa.com / ckasunich@kcsa.com
212-896-1220 / 212-896-1241

SOURCE Hoyos Labs

Hoyos Labs Receives Envisioneering Innovation & Design Award at the 2014 ShowStoppers at the Consumer Electronics Show

For more information on Hoyos Labs and HoyosID, please visit: www.hoyoslabs.com. The app will be available for download later this quarter.

Media Contacts:
Samantha Wolf / Caitlin Kasunich
KCSA Strategic Communications
swolf@kcsa.com / ckasunich@kcsa.com
212-896-1220 / 212-896-1241

SOURCE Hoyos Labs

Inovio Pharmaceuticals CEO Receives 2013 Drug Discovery & Achievement Award

Inovio Pharmaceuticals, Inc. (PRNewsFoto/Inovio Pharmaceuticals, Inc.)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";BLUE BELL, Pa., Nov. 14, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its President & CEO, Dr. J. Joseph Kim, has been selected to receive the 2013 Achievement in Drug Discovery and Development Award from the Korean American Society in Biotech and Pharmaceuticals ("KASBP"). The Society aims to contribute to the growth of drug discovery and development through collaborations and information exchanges between U.S. and Korean pharmaceutical companies and research centers.

The award, sponsored by Daewoong Pharmaceuticals Inc., the leading Korean pharmaceutical company, recognizes Dr. Kim as one of the leaders in moving the field of DNA vaccines from theory to application and development. Dr. Kim founded VGX Pharmaceuticals, which through acquisition became Inovio, and is the leading biotech company advancing DNA vaccines toward commercialization. Inovio is revolutionizing vaccines and immunotherapies to prevent and treat cancers and challenging infectious diseases with products in Phase II development.

Jae-Hun Kim, Ph.D. of Merck Research Laboratories, the current KASBP President, said, "We are very pleased to present the award to Dr. Joseph Kim. The award committee recognized Dr. Kim's significant achievement for invention and development of the technology as a scientist and as a businessman."

Dr. J. Joseph Kim, President & CEO of Inovio Pharmaceuticals said, "This honor recognizes the work of countless scientists who, like me, have pursued the potential of DNA vaccines because we understand the paradigm-changing contribution that DNA vaccines will make to human health. At Inovio, we've shown clinical results that no other organization can match in generating T cells. We believe this technology will change the practice of medicine in treating cancer, HIV, hepatitis, malaria and other infectious diseases. I thank KASBP for this award and for their tireless work in building a bridge between the U.S. and Korea with a goal to advance drug discovery and development."

About the Korean American Society in Biotech and Pharmaceuticals ("KASBP")

The Korean American Society in Biotech and Pharmaceuticals ("KASBP") is a non-profit organization founded in May 2001. The current members include Korean-American professionals working throughout the U.S., mostly in the Biotech or Pharmaceutical field. The member profile includes not only professionals working in 100 pharmaceutical industries (BMS, Novartis, GSK, Merck, Sanofi, J&J, Pfizer, etc.), but also scientists in academics serving universities as faculty members, researchers, post-docs, or graduate students; as well as government employees in the FDA, NIH, and other local and federal government organizations.

KASBP aims to promote scientific recognitions in the community, especially for drug discovery and development. KASBP's activities include annual symposiums to contribute to the advancement of drug discovery, development and other pharmaceutical technology in Korean and U.S. companies. Through a collaboration and networking among the members in Biotech companies, pharmaceutical companies and government funded research centers; KASBP has been helping new drug discovery, technology transfer, drug development and commercialization by Korean companies in Korea and in the U.S markets. One important goal of KASBP is to identify and nurture young Korean-American researchers to become future leaders for Biotech and Pharmaceutical industries in Korea and the U.S. by awarding scholarships.

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis. Partners and collaborators include Roche, the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2012, our Form 10-Q for the quarter ended September 30, 2013, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101 bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com

(Logo: http://photos.prnewswire.com/prnh/20120131/LA44118LOGO)

SOURCE Inovio Pharmaceuticals, Inc.

IRRI thesis intern wins best undergraduate thesis award

Wilson Aala, a former affiliate undergraduate thesis intern in IRRI, received the Undergraduate Best Thesis Award from Philobioscientia (UPLB Life Sciences Society) during the organization's 28th anniversary celebration on 2 August 2012.

Wilson's award-winning undergraduate thesis was titled Morphological and molecular characterization of novel salt-tolerant germplasms from the Philippines and Bangladesh. He was supervised by Glenn Gregorio, IRRI scientist and breeder.

Learn more about IRRI (www.irri.org) or follow us on the social media and networks (all links down the right column).

reade more...

Pages

.